Les tumeurs solides emploient diverses stratégies afin de se maintenir dans l’organisme et d’échapper à l’inhibition du système immunitaire. Un des mécanismes les plus puissants est la production de la cytokine Transforming Growth Factor Beta (TGF-bêta). Cependant, cette cytokine est sécrétée dans le micro-environnement tumoral sous une forme inactive, incapable de se lier à son récepteur et donc d’exercer ses fonctions hautement immunosuppressives. Ces travaux de thèse démontrent qu’une population de lymphocytes T (LT) CD4+ dite T régulateurs (Tregs), qui exprime le facteur de transcription Forkhead box P3 (Foxp3), est responsable de l’activation du TGF-bêta au sein de la tumeur. Nous avons montré que parmi les cellules du système immunitaire, les Tregs constituent la principale population exprimant l’intégrine avb8 (Itgb8), protéine responsable de l’activation du TGF-bêta. L’absence de l’Itgb8 spécifiquement à la surface des Tregs entraîne une forte diminution de la croissance tumorale. Par conséquent, l’activation de la signalisation du TGF-bêta est réduite dans les LT CD8+ qui infiltrent la tumeur, conduisant à une exacerbation de leurs fonctions cytotoxiques et donc à une élimination accrue des cellules tumorales. La relevance de ces données obtenues chez la souris a été confirmée chez l’Homme à la fois par des approches ex vivo sur des tumeurs fraîches ainsi que par des approches bio-informatiques et biostatistiques à partir d’étude de cohortes de patients. Nous proposons donc que les Tregs et les cellules tumorales travaillent de concert pour fournir une source bio-active de TGF-bêta capable de réprimer efficacement la réponse immunitaire anti-tumorale et donc de permettre à la tumeur d’échapper au système immunitaire / Solid tumors employ diverse strategies to be maintained in the organism and escape the suppression mediated by the immune system. One of the most powerful mechanisms they use is through the production of Transforming Growth Factor Beta (TGF-beta). However, this cytokine is secreted within the tumor microenvironment in its inactive form, unable to bind to its receptor and exert its highly immunosuppressive functions. The present thesis project demonstrates that a population of CD4+ T lymphocytes called regulatory T cells (Tregs), which express the transcription factor Forkhead box P3 (Foxp3), is responsible for TGF-beta activation in tumors. We show that among the cells of the immune system, Tregs constitute the main population expressing the integrin avb8 (Itgb8) which is responsible for TGF-beta activation. The absence of Itgb8 specifically on Tregs surface leads to strong decrease of tumor growth. As a result, TGF-beta signaling pathway is impaired in tumor infiltrating CD8+ T lymphocytes leading to exacerbation of their cytotoxic and efficient elimination of tumor cells. The relevance of these data obtained in mice was confirmed in the human pathology by ex vivo approaches using fresh tumors as well as by bioinformatics and biostatistics approaches from studies on patient cohorts. We propose that Tregs and tumor cells cooperate to provide a bioactive source of TGF-beta which is able to efficiently repress the anti-tumor response and thus allowing tumors to escape the immune system

No description available.

Le TGF[bêta] est une cytokine anti-inflammatoire impliquée dans plusieurs types de cancer. Il joue le rôle à la fois de suppresseur de tumeurs et d'oncogène. En effet, selon le stade de progression de la tumeur, il peut avoir un effet protecteur ou promoteur de la tumorigénèse. Les mécanismes par lesquels le TGF[bêta] exerce ses fonctions dans la carcinogénèse ne sont pas bien compris. Il est important d'élucider ces mécanismes afin de pouvoir développer de nouveaux traitements permettant de contrer les effets tumorigénique de ce facteur de croissance. Le TGF[bêta] interagit avec une panoplie de facteurs au cours de son processus de maturation et d'activation. On compte parmi eux la furine, la plasmine, la thrombospondine, les intégrines et les métalloprotéases. Toutes ces molécules peuvent être impliquées dans les processus néoplasiques. L'étude du rôle de leurs interactions dans la tumorigénèse permettrait de mieux comprendre les effets du TGF[bêta]. Une des cibles importantes de l'étude des interactions entre le TGF[bêta] et les acteurs de son processus de maturation et d'activation est la convertase de proprotéine furine. Cet enzyme est responsable de la maturation de plusieurs substrats impliqués dans le cancer tels que le TGF[bêta], le VEGF, le PDGF, la MT1-MMP et l'IGF-1. La maturation de tous ces composés favorise le développement des tumeurs et des métastases en augmentant la prolifération des cellules tumorales, leur capacité d'invasion et l'angiogénèse au coeur des tumeurs solides et des métastases.Le TGF[bêta] étant un susbtrat important de la furine, le but de ce projet est de caractériser le rôle de la maturation du TGF[bêta] par la furine dans la tumorigénèse. Pour ce faire, nous avons utilisé un modèle in vitro de cellules cancéreuses humaines, les HT1080, et un modèle in vivo de progression tumorale chez les souris nu/nu. Nous avons déterminé par différentes techniques telles que la zymographie, les essais d'adhésion, les essais d'invasion sur matrice de collagène de type IV, les essais de motilité, l'incorporation de thymidine tritiée et le PCR quantitatif en temps réel, que la maturation du TGF[bêta] par la furine a un effet protecteur dans les phases précoces du développement tumoral et promoteur sur le développement plus tardif du cancer. En fait, la maturation du TGF[bêta] par la furine permet de maintenir des concentrations plus élevées de TGF[bêta] bioactif dans l'environnement tumoral. Ceci permet l'inhibition de la prolifération cellulaire. Toutefois, cette forte présence de TGF[bêta] au niveau de la tumeur induit, par l'augmentation de l'adhésion et de la motilité cellulaire, la migration de type amoeboïde observée dans plusieurs stades de la tumorigénèse dont la dissémination lymphatique et l'extravasation. De plus, par la production de MMP-2 active et la formation d'invadopodes, le TGF[bêta] induit la migration de type mésenchymal surtout observée au début de l'invasion tumorale et au cours du processus d'intravasation. Par ailleurs, il nous a été impossible de déterminer le rôle exact de la maturation du TGF[bêta] par la farine sur l'angiogénèse, un facteur important dans le maintien des tumeurs solides volumineuses et des métastases. En fait, globalement, elle semble favoriser l'angiogénèse par l'expression de la furine et du VEGF, l'activation de la MT1-MMP et la maturation de la MMP-2, tous des facteurs pro-angiogéniques. Elle permet aussi l'induction de l'expression de PAI-1 qui est plutôt un facteur anti-angiogénique. À l'aide d'un système de reconstitution de l'activité du TGF[bêta] chez les cellules dont la furine est inhibée, nous avons déterminé que le TGF[bêta] est fortement responable des effets de la furine sur la tumorigénèse et ce, à plusieurs niveaux. Il est responsable de l'effet de la furine sur la prolifération, la production de MMP-2, l'invasion, le phénotype cellulaire et la transition d'une migration de type mésenchymal à une migration de type amoeboïde. Il est également partiellement impliqué dans le rôle de la furine sur la formation des invadopodes et la motilité cellulaire. Par contre, pour ces deux derniers processus et au niveau de l'adhésion cellulaire, d'autres substrats de la furine semblent nécessaire pour qu'elle accomplisse ses fonctions.

<p>The transforming growth factor beta (TGF-beta) signaling pathway is a critical regulator of multiple biological processes that are involved in cancer progression, such as proliferation, migration, invasion and metastasis. TGF-beta ligands bind to multiple high-affinity receptors (TbetaRI, TbetaRII, TbetaRIII), whose expression on the cell surface, and subsequent ability to transduce signaling, can be modulated by ectodomain shedding. </p><p> TbetaRIII, also known as betaglycan, is the most abundantly expressed TGF-beta receptor. TbetaRIII suppresses breast cancer progression through inhibiting migration, invasion, metastasis, and angiogenesis. TbetaRIII binds TGF-beta ligands, with membrane-bound TbetaRIII presenting ligand to enhance TGF-beta signaling. However, TbetaRIII can also undergo ectodomain shedding, releasing soluble TbetaRIII, which binds and sequesters ligand to inhibit downstream signaling. To investigate the relative contributions of soluble and membrane-bound TbetaRIII on TGF-beta signaling and breast cancer biology, here I describe TbetaRIII mutants with impaired (Delta-Shed-TbetaRIII) or enhanced ectodomain shedding (SS-TbetaRIII). Relative to wild-type (WT)-TbetaRIII, Delta-Shed-TbetaRIII increased TGF-beta signaling and blocked TbetaRIII's ability to inhibit breast cancer cell migration and invasion. Conversely, SS-TbetaRIII, which increased soluble TbetaRIII production, decreased TGF-beta signaling and increased TbetaRIII-mediated inhibition of breast cancer cell migration and invasion. </p><p> TbetaRI is released from the cell surface by a common sheddase of the A disintegrin and metalloproteinase (ADAM) family, ADAM17. This shedding event results in a downregulation of TGF-beta signaling. Here, I present evidence that a closely related protease, ADAM10, may be a novel sheddase for TbetaRI. A specific ADAM10 inhibitor was able to increase cell surface expression of TbetaRI, and decrease levels of circulating soluble TbetaRI in vivo. Interestingly, inhibition of ADAM10 concurrently increased shedding of TbetaRIII, and was able to alter TGF-beta signaling in a TbetaRIII-dependent manner. </p><p> </p><p> Together, these studies suggest that ectodomain shedding of TGF-beta receptors is an important determinant for regulation of TGF-beta-mediated signaling and biology.</p> / Dissertation

The v-rel oncogene is the most efficiently transforming member of the Rel/NF-κB family of transcription factors. Identification of genes or signal transduction pathways that contribute to v-Rel transformation provide insight into the mechanisms of tumorigenesis by Rel/NF-κB proteins. In these studies, the contribution of TGF-β/Smad signaling to v-Rel transformation was assessed. TGF-β/Smad signaling regulates several cellular processes, including growth, differentiation, and apoptosis and has been implicated in a number of different cancers. Using microarray technology and Northern blot analysis, key components of the TGF-β/Smad pathway (tgf-β2 and tgf-β3 ligands, TGF-β type II receptor, and receptor-activated smad3) were identified with upregulated mRNA expression in v-Rel-transformed fibroblasts and lymphoid cells relative to control cells. A corresponding change in their protein levels was also observed. Further analysis revealed elevated levels of the phosphorylated, active form of Smad3, which correlated with its increased DNA-binding activity in v-Rel transformed cells. In contrast, the overexpression of c-Rel resulted in little to no alteration in the RNA and protein expression of members of the TGF-β/Smad pathway. Further studies demonstrated that elevated TGF-β/Smad signaling is required for the transforming ability of v-Rel. Blocking TGF-β signaling with a kinase inhibitor of TGF-β type I receptor inhibited the activation of Smad3 and dramatically reduced the ability of v-Rel transformed cells to form colonies in soft agar. Overexpression of a constitutively active form of Smad3 in the inhibitor-treated cells restored their ability to form colonies in soft agar close to the levels seen in untreated cells. Additional experiments with dominant negative Smad3 also revealed its ability to hinder the oncogenic potential of v-Rel. In complementary experiments, a stimulatory effect on v-Rel transformation was observed with cells treated with recombinant TGF-β2 ligand or overexpressed with wild-type Smad3. Taken together, these studies demonstrate that TGF-β signaling is crucial for the transformation potential of v-Rel and is primarily mediated by Smad3 activity. / text

Gastrulation is the process by which the three germ layers are generated during vertebrate development. Nodal ligands, which form a subgroup of the Transforming Growth Factor β (TGFβ) superfamily, regulate the expression several transcription factors implicated in gastrulation. Among these are the paired-like homeodomain transcription factors Goosecoid (Gsc) and Mixl1. At the molecular level, Gsc has been described to function as a transcriptional repressor by directly binding to paired homedomain binding sites on target promoters. Here, I describe a novel mechanism of transcriptional repression by Gsc. Using a molecular and embryological approach, I demonstrate that the forkhead transcription factor Foxh1, a major transducer of Nodal signaling, associates with Gsc which in turn recruits histone deacetylases to negatively regulate Mixl1 expression during early mouse development. Post-translational modification of transcription factors by SUMO proteins represents an important mechanism through which their activity is controlled. Here, I also demonstrate that Gsc is sumoylated in mammalian cells by members of the PIAS family of proteins and this modification potentiates the repressive activity of Gsc on direct targets such as the Xbra and Gsc promoters, but not on indirect targets such as Mixl1. Taken together, work presented in this thesis describes two novel mechanisms of transcriptional repression by Gsc.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Este estudo in vitro teve como objetivo avaliar os efeitos moleculares do TGF-&beta;1, com diferentes períodos de suplementação, sobre a formação do fenótipo osteogênico das células MC3T3-E1, comparando-os com células tratadas com AA+&beta;-GP suplementados com Dex e/ou TGF-&beta;1, sem e com a neutralização dos receptores de TGF-&beta;1. A expressão gênica do próprio TGF-&beta;1 e Smad3 foram analisadas, bem como, a diferenciação das células osteogênicas e a biomineralização. As células tratadas com TGF-&beta;1 sem neutralização de receptores apresentam efeito inibitório nos estágios mais avançados da diferenciação dos osteoblastos e da biomineralização in vitro, mas expressarem alguns marcadores importantes envolvidos na mineralização. Observaram-se nódulos de mineral em todos os tratamentos das células que tiveram os receptores de TGF-&beta;1 neutralizados, mas houve uma diminuição na expressão de alguns genes. Os resultados confirmam a complexidade da via de sinalização do TGF-&beta;1, mostrando que existem lacunas para que seja entendido o mecanismo dessa molécula na biologia osteoblástica. / This in vitro study aimed to evaluate the molecular effects of TGF-&beta;1, with different supplementation time periods on the establishment of MC3T3-E1 cells, comparing with cells treated with AA+&beta;-GP supplemented with Dex and/or TGF-&beta;1, without or with neutralization of TGF-&beta;1 receptors. The gene expression of the TGF-&beta;1 and Smad3 were analyzed, as well as the osteoblast differentiation and biomineralization. The cells treated with TGF-&beta;1 without neutralization of receptors have had inhibitory effect on some important stages of osteoblast differentiation and biomineralization in vitro, but expressed some important mineralization markers. Mineral nodules were observed in all treatments of cells with their TGF-&beta;1 receptors neutralized, but there was a decrease in the expression of some important genes. The results confirm the complexity of the pathway signaling of TGF-&beta;1, showing that there are gaps for understand the mechanisms of this molecule in the biology of osteoblasts.

According to statistics from the American Heart Association, valvular heart disease directly leads to about 20,000 deaths a year and contributes to an additional 50,000. While significant advancements have been made in the treatment options available for valvular heart disease, complications still occur. For this reason, the future of valvular heart disease treatment lies in understanding the physiology of the heart valve, and subsequently bioengineering a valve from one's own tissue to mimic native valve processes. Valvular interstitial cells (VICs) are the major cell type populating the valve matrix. In the inactive fibroblast-like state, these cells are responsible for extracellular matrix deposition. Activated VICs display a myofibroblast morphology characterized by the expression of alpha smooth muscle actin and are responsible for valve maintenance and repair. The activation of VICs is hypothesized to be stimulated by mechanical tension, which, in the presence of TGF-â1 allows the complete differentiation of VICs from the inactive to the active form. However, little is known about the potential for reversal or dedifferentiation from the active to inactive state. The purpose of this study was to determine whether substrate stiffness, the mechanical tension hypothesized to initiate VIC activation, modulates alpha smooth muscle actin expression in the presence and absence of TGF-â1. To mimic conditions found in vivo, substrates were varied from physiologic to pathological stiffness levels. Results showed that when freshly isolated VICs are cultured in the presence of serum, alpha smooth muscle actin expression increased on all substrate stiffnesses. In TGF-â-free medium, there was an apparent increase on all stiffness levels as well, but a statistical significance between groups could not be demonstrated. Immunoblots used to detect TGF-â1 showed that intracellular TGF-â1 was upregulated in VICs cultured in the presence of serum compared to those cultured in TGF-â-free medium. Taken together, these results suggest that freshly isolated VICs become activated, as indicated by increased expression of alpha smooth muscle actin, on all substrate levels in the presence of serum. It also appears as though unknown factors which are present in serum are required to stimulate significant autocrine production of TGF-â1. To determine whether VICs which had transitioned to the myofibroblast phenotype had the ability to dedifferentiate, cells were cultured on polystyrene for a minimum of four days then replated on substrates of varying stiffness. Analysis of alpha smooth muscle actin expression showed that, in the presence of serum and when replated on all of substrates used, alpha smooth muscle actin expression decreased, suggesting that these cells indeed have the potential to dedifferentiate. A change in cell morphology to a more rounded phenotype as well as the loss of visible stress fibers further supported this possibility. These studies represent a unique approach to studying phenotypic differentiation of valvular interstitial cells. Using acrylamide substrates of varying stiffness, and growth factor free media, we have shown that by altering substrate stiffness, changes in alpha smooth muscle actin expression consistent with differentiation and dedifferentiation can be induced. This potential for dedifferentiation suggests that in engineering the next generation of bioartificial valves, it may be possible to use the patient's own cells to seed the manufactured scaffold. This would avoid complications associated with current treatments, including immune rejections.

Infection with human gastrointestinal (GI) parasites, such as Trichuris trichiura, affects more than billion people worldwide, causing significant morbidity and health problems especially in poverty-stricken developing countries. Despite extensive research, the mechanisms of induction and regulation of effector immune responses against these parasites are incompletely understood, which hinders the development of anti-parasite therapies. Infection with GI parasite is usually chronic suggesting that parasites are capable of modulating immune responses of their host to prevent expulsion. However, mechanisms by which parasites control host immunity to allow infection are still ill-defined. The aim of this PhD study was to characterise the role of different immunoregulatory mechanisms in immunity to GI parasite infection, with a focus on dendritic cells (DCs), regulatory T cells (Tregs) and the regulatory cytokine transforming growth factor β (TGF-β).Here we showed for the first time that loss of TGF-β-activating integrin alphavβ8 specifically on DCs resulted in protection from chronic infection with Trichuris muris, a mouse model of T. trichiura infection in man. Accelerated expulsion was immune-mediated and although increased levels of protective Th2 cytokines were observed very early during infection, elevated levels of non-protective Th1 cytokines were also detected. Partial depletion of CD4+ or FcεRI+ cells had no effect on the observed phenotype. Since deletion of alphavβ8 on DCs results in decreased numbers of Tregs in the gut, we tested whether depletion of Tregs using a mouse model that allows conditional ablation of Foxp3+ Tregs (DEREG mice) would alter infection development. Although transient Treg depletion at the beginning of infection had no major effect on expulsion kinetics, we observed a tendency for enhanced Th2 responses in DEREG mice. Moreover, even though DC-mediated TGF-β activation via alphavβ8 integrin was essential for T. muris infection development, transient depletion of DCs had no effect on the induction of Th2 responses or parasite expulsion. These data indicate a novel role for the TGF-β-activating integrin alphavβ8 and DCs in regulating effector immune responses during T. muris infection and may contribute to the development of new anti-parasite therapies.